

Mid-term Business Plan 2022: Reshaping the Business Foundation

Under the Mid-term Business Plan 2022, we will significantly reshape our business foundation through the “establishment of growth engines” and the “building of a flexible and efficient organization.”

In terms of the “establishment of growth engines,” we will not only continue to focus on R&D and business growth in our three focus areas, but also promote drug discovery utilizing external networks, centering on our presence in Japan and the United States. In addition, we will also work to strengthen our innovation base through new approaches to drug discovery, such as the realization of precision medicine by leveraging cutting-edge research results and biomarkers. Moreover, in order to obtain results even in highly uncertain areas, we will focus on

improving the probability of success and efficiency in research and development through targets that anticipate changes in the scientific and medical environment; evidence-based and objective evaluation and decision-making; thorough risk management; utilizing biomarkers and big data.

Another strategy pillar of the Mid-term Business Plan 2022 is the “building of a flexible and efficient organization” to support these growth engines. We will use digital transformation to enable our organization and talent to identify changes in the external environment and adapt proactively and flexibly, while maintaining the ability to do things diligently, which is called “CHANTO”: deliver the highest performance.

